Can You Switch from Mounjaro to Zepbound for Weight Loss?
Yes, you can switch from Mounjaro (tirzepatide) to Zepbound (also tirzepatide) for weight management. Both drugs contain the same active ingredient—a dual GLP-1 and GIP receptor agonist—and are made by Eli Lilly. Mounjaro is FDA-approved for type 2 diabetes but commonly prescribed off-label for weight loss, while Zepbound is specifically approved for chronic weight management in adults with obesity or overweight plus related conditions.[1] Switching is straightforward since the formulations are identical, allowing equivalent dosing.
What's the Difference Between Mounjaro and Zepbound?
They differ mainly in labeling and approval: Mounjaro targets blood sugar control, Zepbound targets weight loss (aiming for at least 5% body weight reduction). Insurance coverage often favors Zepbound for obesity claims, potentially lowering out-of-pocket costs. Doses range from 2.5 mg to 15 mg weekly for both, with no need for dose conversion when switching.[2]
How Do You Switch Doses Safely?
Start Zepbound at your current Mounjaro dose—no titration reset needed, as they're bioequivalent. For example, if you're on Mounjaro 5 mg weekly, continue Zepbound 5 mg. Your doctor may adjust based on response or side effects. Administer via prefilled pens subcutaneously, ideally same day/time weekly. Consult your prescriber first to confirm coverage and monitor for issues like nausea during any overlap or transition.[3]
Will Insurance Cover the Switch?
Coverage varies: Medicare often denies GLP-1s for weight loss, but Zepbound may qualify under Part D for obesity. Private insurers like UnitedHealthcare or Blue Cross more readily cover Zepbound than off-label Mounjaro. Without coverage, Zepbound costs $1,000-$1,300 monthly; LillyDirect offers savings cards capping copays at $25 for eligible patients. Check your plan or pharmacy benefit manager.[4]
What Side Effects or Risks Come with Switching?
Common side effects match across both: nausea (up to 44% at higher doses), diarrhea, vomiting, constipation, and injection-site reactions. Rare risks include thyroid tumors (boxed warning), pancreatitis, or gallbladder issues. No unique switch-related risks reported, but abrupt changes can worsen GI symptoms. Long-term data shows 15-20% average weight loss over 72 weeks on tirzepatide.[5] Patients with gastroparesis or medullary thyroid cancer history should avoid.
Are There Alternatives if Switching Isn't Ideal?
Stick with Mounjaro if diabetes is primary. Competitors include semaglutide (Wegovy/Ozempic, 15% weight loss average) or liraglutide (Saxenda). Upcoming options: retatrutide (triple agonist in trials). Diet/exercise alone yields 5-10% loss but lower adherence.[6]
| Drug | Active Ingredient | Weight Loss Avg. | Monthly Cost (No Coverage) |
|------|-------------------|------------------|----------------------------|
| Mounjaro/Zepbound | Tirzepatide | 15-21% | $1,000-$1,300 |
| Wegovy | Semaglutide | 15% | $1,300-$1,500 |
| Saxenda | Liraglutide | 5-10% | $1,300 |
Sources:
[1] FDA.gov - Zepbound Approval (fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/zepbound-tirzepatide)
[2] Eli Lilly - Product Labels (lilly.com/zepbound, lilly.com/mounjaro)
[3] NEJM - Tirzepatide SURMOUNT Trials (nejm.org/doi/full/10.1056/NEJMoa2206038)
[4] GoodRx - Coverage Data (goodrx.com/zepbound/insurance-coverage)
[5] Lilly Prescribing Info (pi.lilly.com/us/zepbound-uspi.pdf)
[6] JAMA - GLP-1 Comparisons (jamanetwork.com/journals/jama/fullarticle/2807342)